Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis

Table 1 Baseline characteristics of 291 patients at the time of completing the MISS

Characteristic	Value in patient sample
Sex, female	181 (62.2)
Age, mean +/- SD years	59.4 +/- 12.4
Diagnosis
Rheumatoid arthritis	249 (85.6)
Psoriatic arthritis	42 (14.4)
Disease activity
Disease activity score 28, median (IQR)^a	2.5 (1.7 to 3.2)
Physician’s global assessment, median (IQR), (0 to 10 scale)^b	2.0 (1.0 to 3.0)
Erythrocyte sedimentation rate (mm/hour)	11.0 (5.0 to 22.0)
MTX use
Route of administration, oral	194 (66.7)
Dose, mg/week, median (IQR)	20.0 (12.5 to 25.0)
Other medication
NSAIDs	145 (49.9)
Proton-pump inhibitors	127 (43.6)
Anti-emetics	5 (1.7)
Oral steroids	31 (10.7)
Other DMARDs^c	72 (24.7)

Characteristics are as calculated at the time of completing the MISS except where indicated otherwise. Values are number (%), except where indicated otherwise. ^aDisease activity score 28 was determined in 266 patients (274 rheumatoid arthritis and 19 psoriatic arthritis patients); ^bphysician’s global assessment was determined in 268 patients; ^cof 72 patients on other DMARDs, 26 were on DMARDs (plaquenil, n = 24; leflunomide, n = 2) and 46 were on biologic agents (infliximab, n = 24; adalimumab, n = 10; etanercept, n = 9; abatecept, n = 2; golimumab, n = 1). MISS, methotrexate intolerance severity score; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; DMARDs, disease-modifying anti-rheumatic drugs.

ISSN: 1478-6362